236 related articles for article (PubMed ID: 37770765)
1. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M; Porta FM; D'Ercole M; Pescia C; Sajjadi E; Cursano G; De Camilli E; Pala O; Mazzarol G; Venetis K; Guerini-Rocco E; Curigliano G; Viale G; Fusco N
Virchows Arch; 2024 Jan; 484(1):3-14. PubMed ID: 37770765
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
J Clin Oncol; 2023 Aug; 41(22):3867-3872. PubMed ID: 37284804
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
Arch Pathol Lab Med; 2023 Sep; 147(9):993-1000. PubMed ID: 37303228
[TBL] [Abstract][Full Text] [Related]
4. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
5. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
6. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
7. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
8. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
[TBL] [Abstract][Full Text] [Related]
9. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
10. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
11. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
12. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
[TBL] [Abstract][Full Text] [Related]
13. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
14. UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA; Tan PH; Quinn C; Provenzano E; Shaaban AM; Deb R; Callagy G; Starczynski J; Lee AHS; Ellis IO; Pinder SE
J Clin Pathol; 2023 Apr; 76(4):217-227. PubMed ID: 36564170
[TBL] [Abstract][Full Text] [Related]
15. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
16. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
[TBL] [Abstract][Full Text] [Related]
17. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
18. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
19. Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
Chao WR; Lee MY; Lee YJ; Sheu GT; Han CP
Virchows Arch; 2022 May; 480(5):1023-1030. PubMed ID: 35226147
[TBL] [Abstract][Full Text] [Related]
20. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
